Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its ...

The G7 15 Day CGM in use. [Image courtesy of Dexcom] Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month. The San ...

The Smart Basal offering with the G7 CGM. [Images courtesy of Dexcom] Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer. The ...

Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and ...